Boston-based BioDirection has raised a $4 million Series B round to back its point-of-care traumatic brain injury test Tbit. The financing is expected to enable the startup to finalize development and to start commercial planning for the test.
Researchers at Oregon State University have combined three cancer drugs in a nanoparticle system to treat deadly metastatic skin cancers by targeting the lymph nodes.
Researchers at Rice University claim to have invented the "fastest-moving molecules ever seen in solution," developing a molecular machine that propels itself using ultraviolet light. Just a proof of concept for now, the tiny submersibles could potentially carry drugs in the future.
Oasmia Pharmaceutical (STO:OASM) has made another change to its upcoming NASDAQ IPO. The nanotechnology specialist is now planning to hand out one warrant for every two shares it sells in the IPO, positioning it to boost its fundraising haul by more than 60% if investors take up the option to buy stock at the predefined price.
How will Google Life Sciences create its highly anticipated nanotech diagnostic hordes? Precision NanoSystems might know. It's nabbed a $13.4 million Series A round to back its NanoAssemblr platform that can be used to create next-gen nanoparticle therapeutic and diagnostic agents targeted to the cellular level.
The shape of molecules used to deliver drugs determines how and when the drugs are able to interact with their target. And having the right tools to operate that intricate machinery is an important part of that process. Researchers have developed a "wrench" using the chirality of molecules at the nanoscale to create customized compounds that can perform specific functions.
Scientists at the University of California, San Diego, have developed nanoparticles that could act as human platelets in the blood, helping drugs that treat cardiovascular disease and bacterial infections.
Research teams from the U.S. and Ireland are joining forces in the development of nanotechnology to treat pancreatic cancer. With a new grant of £2.9 million ($4.4 million), the international cohort aims to create chemotherapy-delivering treatments for the disease, which has the lowest 5-year survival rate of any common cancer.
Researchers have developed a soft, conductive electronic polymer mesh that can be injected into the brain to monitor and stimulate it at the level of individual neurons. They have published preclinical data on the device in the latest issue of Nature Nanotechnology.
The ability to supercool drug-carrying vesicles inside the body and time the exact moment of crystallization could lead to a targeted approach to drug delivery, researchers at Tel Aviv University have found.